Please assess the completion status of the following clinical trial:

Trial Title: Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Computed tomography (CT) evidence of proximal PE (filling defect in at least one main or segmental pulmonary artery)~* PE symptom duration less than or equal to (\<=)14 days~* Informed consent can be obtained from participant or Legally Authorized Representative (LAR)~* Massive PE (syncope, systemic arterial hypotension, cardiogenic shock, or resuscitated cardiac arrest) or~* Submassive PE (RV diameter-to-LV diameter greater than or equal to \[\>=\] 0.9 on contrast-enhanced chest CT)~Exclusion Criteria:~* Stroke or transient ischemic attack (TIA), head trauma, or other active intracranial or intraspinal disease within one year~* Recent (within one month) or active bleeding from a major organ~* Hematocrit less than (\<) 30 percent (%)~* Platelets \< 100 thousand/microliter (mcL)~* International Normalized Ratio (INR) greater than (\>) 3~* Activated partial thromboplastin time (aPTT) \>50 seconds on no anticoagulants~* Major surgery within seven days of screening for study enrollment~* Serum creatinine \>2 milligrams/deciliter (mg/dL)~* Clinician deems high-risk for catastrophic bleeding~* History of heparin-induced thrombocytopenia (HIT)~* Pregnancy~* Catheter-based pharmacomechanical treatment for pulmonary embolism within 3 days of study enrollment~* Systolic blood pressure less than 80 mm Hg despite vasopressor or inotropic support~* Cardiac arrest (including pulseless electrical activity and asystole) requiring active cardiopulmonary resuscitation (CPR)~* Evidence of irreversible neurological compromise~* Life expectancy \<30 days~* Use of thrombolytics or glycoprotein IIb/IIIa antagonists within 3 days prior to inclusion in the study~* Previous enrollment in the SEATTLE study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EkoSonic® Endovascular System (Type: EXPERIMENTAL): Participants will receive a total of 24 milligrams (mg) of recombinant t-PA infusion, at an infusion rate of 1 milligrams/hour (mg/hr) per device (2 mg/hour for bilateral PE) delivered through the EkoSonic® Endovascular System. This regimen allows for a recombinant t-PA infusion time of 24 hours for one catheter and 12 hours for two catheters, respectively.

Based on this trial design, predict the completion outcome and termination type (if applicable).